Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...

Sam Altman, the CEO of OpenAI, is backing a groundbreaking initiative aimed at extending human lifespan by a decade through ...

The Financial Times today cited sources as saying that OpenAI Chief Executive Sam Altman is participating in the investment. He previously provided the initial $180 million funding round that helped ...

OpenAI CEO Sam Altman backs Retro Biosciences, a San Francisco-based biotech start-up that wants to extend human lifespan by ...

What's trending in Bay Area business news this Friday morning: Twilio, EA Sports, Headlands Brewing, GameOn, 345 California, Retro Biosciences and more.

Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...

Disease-reversal startup Retro Biosciences is aiming for a $1 billion funding round, a spokesperson for the company confirmed ...

OpenAI, in partnership with Retro Biosciences, has recently made significant strides in human longevity research with the ...

We saw several innovative uses of AI in the past week, and a bad slip-up in news sharing. A quick round-up: ...

The race to increase human life span through biotech just got tighter. Retro Biosciences, the AI-powered company whose mission is to develop therapies that reverse age-related disease, has just ...